Ohio negotiates prize freeze on anti-overdose drug

State officials announced this week that Ohio is the first state to negotiate a price freeze with the maker of naloxone, an opiate overdose medication (Source: “Ohio locks in discount for overdose drug,” Chillicothe Gazette, Nov. 30, 2016)

Ohio is the only state to have secured a price freeze with Adapt Pharma, the only manufacturer of FDA-approved nasal naloxone, Narcan. When given to a person overdosing on opioids such as heroin, fentanyl, carfentanil or a prescription opioid, naloxone can limit or stop the overdose by reversing the effects of the opioid on the brain.

The price freeze applies to first responders, law enforcement and community-based organizations. The wholesale cost for two 4 mg doses of the nasal spray is $125, but Ohio agencies will be charged $75, a 40 percent discount.

Attorney General Mike DeWine worked with Adapt Pharma to negotiate a price freeze with hopes that by keeping costs down, more agencies will consider keeping naloxone on hand.

Attend HPIO's 2025 Health Policy Summit on Oct. 9, 2025

With limited resources and growing need, investing in policies that deliver the greatest impact is essential. This event will highlight strategies that improve health and wellbeing while reducing healthcare spending. Speakers will provide evidence-informed research responsive to today’s political climate, focusing on what works and why it matters now more than ever.

Register now